Secondary mitral regurgitation: pathophysiology, proportionality and prognosis

Area of Science:

• Cardiology
• Cardiovascular Medicine
• Medical Devices

Background:

• Secondary mitral regurgitation (SMR) arises from left heart dysfunction and remodeling, often undertreated with poor prognosis.
• Debate exists on whether SMR reflects underlying cardiomyopathy or independently drives poor outcomes in heart failure (HF).
• Current quantitative thresholds for severe SMR and echocardiographic assessment remain challenging.

Purpose of the Study:

• To review the prognostic implications of SMR in heart failure.
• To analyze the contrasting results of recent transcatheter mitral valve repair trials (MITRA-FR and COAPT).
• To explore methods for identifying patients who benefit from SMR intervention.

Main Methods:

• Review of existing literature and randomized controlled trials (RCTs) on SMR and HF interventions.
• Analysis of outcomes from the MITRA-FR and COAPT trials comparing transcatheter mitral valve repair to guideline-directed medical therapy.
• Discussion of echocardiographic quantification challenges and potential new discriminators for intervention success.

Main Results:

• SMR may be an independent prognostic driver in intermediate, not advanced, HF phenotypes.
• The COAPT trial showed significant prognostic benefit of transcatheter repair, unlike MITRA-FR.
• Patient selection, particularly the ratio of MR severity to HF phenotype, influenced COAPT's positive outcome.

Conclusions:

• Transcatheter mitral valve repair can offer prognostic benefits in selected SMR patients.
• Quantifying SMR relative to left ventricular volume may predict intervention success.
• Future efforts should focus on validating new parameters and maintaining a heart-team approach for SMR management.